Publications by authors named "E E Kawata"
Background: While R-CHOP has been one of the standard therapies for untreated high-tumor-burden (HTB) follicular lymphoma (FL) for over 2 decades, obinutuzumab plus bendamustine (OB) is also currently regarded as the standard of care since its approval in 2018 in Japan; however, the long-term efficacy and safety of OB in the daily clinical practice has not been thoroughly evaluated.
Methods: We conducted a multicenter retrospective study for the clinical outcome of 53 patients with HTB FL treated by OB as the frontline therapy between 2018 and 2021 in the Kyoto Hematology Clinical Study Group (KOTOSG). All patients had at least 2-year follow-up period.
Article Synopsis
- Intranasal tumors in dogs are mainly malignant and treated with radiotherapy, but they often return after treatment; combining therapies can improve outcomes.
- The study tested a combination of two drugs, TS-1 and toceranib phosphate, to determine a safe dosage for dogs with these tumors, using a cohort design to assess safety over a month.
- Results showed that the maximum TS-1 dose of 2.0 mg/kg combined with 2.4 mg/kg of toceranib phosphate thrice weekly was well-tolerated, indicating that this combination therapy is safe for treating canine intranasal tumors.
Article Synopsis
- A multi-institutional study examined 100 patients with diffuse large B-cell lymphoma (DLBCL) who were ineligible for transplants after their initial treatment, aiming to create a predictive model for outcomes.
- Key findings revealed that the median age of these patients was 76, with median progression-free survival of 11.5 months and overall survival of 21.9 months.
- Three factors (low lymphocyte-to-monocyte ratio, high lactate dehydrogenase, and high C-reactive protein) were identified as strong predictors of overall survival, leading to the development of the Kyoto Prognostic Index for assessing treatment response in these patients.
Introduction: Skeletal muscle mass is considered a prognostic factor for survival in patients with cancer. In this study, we investigated the associations between skeletal muscle mass, physical function, fatigue, and quality of life(QOL)at diagnosis in patients with hematological malignancies.
Methods: In this study, we included 27 untreated patients with newly diagnosed hematological malignancies who visited our hospital.
Article Synopsis
- Azacitidine (AZA) is a standard treatment for patients with myelodysplastic syndrome (MDS) who cannot undergo transplantation, but early treatment often faces interruptions due to hematological toxicities.
- A multicenter retrospective study involving 212 MDS patients examined factors affecting survival during the early phase of AZA therapy, specifically focusing on severe cytopenia and its impact on patient outcomes.
- The study identified that severe thrombocytopenia and very poor risk cytogenetics are key independent prognostic factors, leading to the creation of the Kyoto Conditional Survival Scoring System to better assess patient risks during AZA treatment.